Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced ...

Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on adva ...

Autonomix Medical, Inc. (AMIX) recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management. The platform enables both sensing and stimulation of nerves through a single device.With the b ...

Patent strengthens Autonomix's intellectual property position in the nerve-mapping and denervation space, supporting the Company's broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company ...

Core Viewpoint - Autonomix Medical, Inc. is participating in the Virtual Investor Closing Bell Series to showcase its innovative medical device technology focused on precision nerve-targeted treatments [2][3]. Company Overview - Autonomix Medical, Inc. is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [5]. - The company's first-in-class platform system technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5][6]. Technology and Applications - The initial development of the technology is aimed at treating pain, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [6]. - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [6]. Event Details - The event will feature a corporate overview by Brad Hauser, President and CEO, and will include a live Q&A session for investors and interested parties [3][4]. - The live video webcast will be accessible on the company's website, with a replay available for 90 days following the event [4].

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to rev ...

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the “What This Means” video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medic ...

Core Insights - Autonomix Medical, Inc. has successfully completed the initial trial phase ("PoC 1") for its innovative pain management technology, demonstrating significant pain reduction in patients with severe pancreatic cancer pain [1][2][5] - The company plans to initiate a follow-on market expansion study ("PoC 2") in Q2 2025, targeting additional visceral cancers and earlier stage pancreatic cancer, potentially doubling the addressable market [1][6][12] Group 1: Trial Results - The PoC 1 trial enrolled 20 patients, achieving clinically meaningful pain reduction with 100% of responders reporting zero opioid use at 7 days post-procedure and 73% remaining opioid-free at 4-6 week follow-up [1][2][8] - Pain relief was statistically significant, with a mean reduction of 3.32 on the Visual Analog Scale (VAS) at 7 days (baseline 7.61 to 4.29), representing a 43.6% improvement, and a mean reduction of 3.95 at 4-6 weeks (baseline 7.95 to 4.00), or 49.7% improvement [8][11] - Responding patients treated via femoral access showed a mean pain reduction of 4.16 at 7 days (baseline 7.81 to 3.65), or 53.3% improvement, and 4.67 at 4-6 weeks (baseline 7.89 to 3.22), or 59.2% improvement [8][11] Group 2: Safety and Quality of Life - The procedure demonstrated a strong safety profile, with no device or procedure-related serious adverse events reported, although there were 8 serious adverse events unrelated to the procedure [8][11] - Patients reported a 76% improvement in global quality of health at 7 days and a 42% improvement at 4-6 weeks post-procedure [8][11] Group 3: Future Directions - The follow-on PoC 2 phase will focus on interventional pain management for additional visceral cancers and earlier stage pancreatic cancer, with an amended trial protocol to gather more data on pain management [6][7][9] - Autonomix's technology platform has the potential to address a wide range of indications beyond cancer pain, including cardiology and chronic pain management [7][12][13]

New patent underscores breadth of application and expansion opportunities for Company's catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, t ...

Core Viewpoint - Autonomix Medical, Inc. is preparing to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval of its innovative medical technology aimed at diagnosing and treating diseases of the nervous system [1][3]. Company Overview - Autonomix Medical, Inc. is focused on advancing technologies for the diagnosis and treatment of nervous system diseases, featuring a first-in-class platform system technology that includes a catheter-based microchip sensing array [4]. - The technology is designed to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [4]. Clinical Development - The company is initially developing its technology for pain treatment, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5]. - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [5]. Expert Engagement - Autonomix has engaged a team of U.S. and international medical experts in interventional radiology and cancer pain to guide its clinical and regulatory path, ensuring that pre-clinical and clinical studies align with the needs for the FDA De Novo submission expected in 2026 [1][2][3].